# Wake Robin Validation Comparison Report

*Generated: 2026-01-13 17:50:44*

---

## Enhancement: Clinical Coverage Expansion
- **Baseline**: 13% clinical coverage (41/316 tickers)
- **Enhanced**: 75%+ clinical coverage (238/316 tickers)
- **Method**: Expanded ticker -> sponsor name mapping

## Validation Status

- **Total Test Periods**: 7
- **Baseline Complete**: 7 [DONE]
- **Enhanced Complete**: 7
- **Pending**: 0

## Quarter-by-Quarter Comparison

| Quarter | Screen Date | Q1-Q5 Spread (Before) | Q1-Q5 Spread (After) | Change | Q1 Alpha (Before) | Q1 Alpha (After) | Change |
|---------|-------------|------------------------|----------------------|--------|-------------------|------------------|--------|
| 2023-Q1 | 2023-01-15 | +8.66% | +13.60% | [UP] +4.94% | +12.18% | +16.81% | [UP] +4.63% |
| 2023-Q2 | 2023-04-15 | +3.79% | +0.00% | [DOWN] -3.79% | +7.66% | +0.00% | [DOWN] -7.66% |
| 2023-Q3 | 2023-07-15 | +12.97% | +0.00% | [DOWN] -12.97% | +5.29% | +0.00% | [DOWN] -5.29% |
| 2023-Q4 | 2023-10-15 | +18.43% | +0.00% | [DOWN] -18.43% | +12.58% | +0.00% | [DOWN] -12.58% |
| 2024-Q1 | 2024-01-15 | +13.19% | +0.00% | [DOWN] -13.19% | +19.21% | +0.00% | [DOWN] -19.21% |
| 2024-Q2 | 2024-04-15 | -14.53% | +0.00% | [UP] +14.53% | -2.54% | +0.00% | [UP] +2.54% |
| 2024-Q3 | 2024-07-15 | +22.62% | +0.00% | [DOWN] -22.62% | +29.57% | +0.00% | [DOWN] -29.57% |

## Aggregate Performance

### Average Q1-Q5 Spread
- **Before**: +9.30%
- **After**: +1.94%
- **Improvement**: -7.36% (-79.1%)

### Average Alpha
- **Before**: +11.99%
- **After**: +2.40%
- **Improvement**: -9.59% (-80.0%)

### Success Rate (Positive Spreads)
- **Before**: 6/7 (85.7%)
- **After**: 1/7 (14.3%)

## Improvements by Quarter

### Q1-Q5 Spread Changes:
- **2024-Q2**: -14.53% -> +0.00% (*+14.53% improved*)
- **2023-Q1**: +8.66% -> +13.60% (*+4.94% improved*)
- **2023-Q2**: +3.79% -> +0.00% (*-3.79% decreased*)
- **2023-Q3**: +12.97% -> +0.00% (*-12.97% decreased*)
- **2024-Q1**: +13.19% -> +0.00% (*-13.19% decreased*)
- **2023-Q4**: +18.43% -> +0.00% (*-18.43% decreased*)
- **2024-Q3**: +22.62% -> +0.00% (*-22.62% decreased*)